Discussing the phase 3 SPLASH study (177Lu-PNT2002) from Point Biopharma, and how it may compare to Pluvicto in mCRPC

Executed on:Aug 25, 2022 3:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Minnesota (formerly Hopkins)

Associate Director for Translational Research at the Masonic Cancer Center & Director of Genitourinary Oncology Hematology, Oncology, and Transplantation) at the University of Minnesota Medical School.
Clinical interest is the management of prostate cancer and other genitourinary malignancies. 
Research focuses on developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches. 

Interview Goal

This conversation will focus on the standard of care for metastatic castration resistant prostate cancer and the potential of new therapies in development with a specific focus on 177Lu-PNT2002. We will dig into the recent data from the Phase 3 SPLASH study of 177Lu-PNT2002 from Point Biopharma,and how it may compare to Pluvicto with an oncologist who treats mCRPC.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.